Chris Tran
Overview
Explore the profile of Chris Tran including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
4291
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kim J, Kim B, Cai L, Choi H, Ohgi K, Tran C, et al.
Nature
. 2022 Jul;
607(7919):E11.
PMID: 35790797
No abstract available.
2.
Li J, Liu J, Zhang X, Clausen V, Tran C, Arciprete M, et al.
Drug Metab Dispos
. 2021 May;
49(7):572-580.
PMID: 33941543
Givosiran is an -acetylgalactosamine-conjugated RNA interference therapeutic that targets 5'-aminolevulinate synthase 1 mRNA in the liver and is currently marketed for the treatment of acute hepatic porphyria. Herein, nonclinical pharmacokinetics...
3.
Liu J, Li J, Tran C, Aluri K, Zhang X, Clausen V, et al.
Bioanalysis
. 2019 Dec;
11(21):1967-1980.
PMID: 31829056
Advancements in RNA interference therapeutics have triggered development of improved bioanalytical methods for oligonucleotide metabolite profiling and high-throughput quantification in biological matrices. HPLC coupled with high-resolution mass spectrometry (LC-HRMS) methods...
4.
Discovery of a novel deaminated metabolite of a single-stranded oligonucleotide by mass spectrometry
Li J, Liu J, Enders J, Arciprete M, Tran C, Aluri K, et al.
Bioanalysis
. 2019 Dec;
11(21):1955-1965.
PMID: 31829055
A novel single-stranded deaminated oligonucleotide metabolite resulting from a REVERSIR™ oligonucleotide was discovered and identified in monkey liver after subcutaneous administration. REVERSIR-A and its metabolites were extracted from biological matrices...
5.
Janas M, Zlatev I, Liu J, Jiang Y, Barros S, Sutherland J, et al.
Nucleic Acids Res
. 2019 Mar;
47(7):3306-3320.
PMID: 30820542
For oligonucleotide therapeutics, chemical modifications of the sugar-phosphate backbone are frequently used to confer drug-like properties. Because 2'-deoxy-2'-fluoro (2'-F) nucleotides are not known to occur naturally, their safety profile was...
6.
Clegg N, Wongvipat J, Joseph J, Tran C, Ouk S, Dilhas A, et al.
Cancer Res
. 2012 Jan;
72(6):1494-503.
PMID: 22266222
Continued reliance on the androgen receptor (AR) is now understood as a core mechanism in castration-resistant prostate cancer (CRPC), the most advanced form of this disease. While established and novel...
7.
Palaskas N, Larson S, Schultz N, Komisopoulou E, Wong J, Rohle D, et al.
Cancer Res
. 2011 Jun;
71(15):5164-74.
PMID: 21646475
In contrast to normal cells, cancer cells avidly take up glucose and metabolize it to lactate even when oxygen is abundant, a phenomenon referred to as the Warburg effect. This...
8.
Jung M, Ouk S, Yoo D, Sawyers C, Chen C, Tran C, et al.
J Med Chem
. 2010 Mar;
53(7):2779-96.
PMID: 20218717
A structure-activity relationship study was carried out on a series of thiohydantoins and their analogues 14 which led to the discovery of 92 (MDV3100) as the clinical candidate for the...
9.
Tran C, Ouk S, Clegg N, Chen Y, Watson P, Arora V, et al.
Science
. 2009 Apr;
324(5928):787-90.
PMID: 19359544
Metastatic prostate cancer is treated with drugs that antagonize androgen action, but most patients progress to a more aggressive form of the disease called castration-resistant prostate cancer, driven by elevated...
10.
Vivanco I, Palaskas N, Tran C, Finn S, Getz G, Kennedy N, et al.
Cancer Cell
. 2007 Jun;
11(6):555-69.
PMID: 17560336
Although most oncogenic phenotypes of PTEN loss are attributed to AKT activation, AKT alone is not sufficient to induce all of the biological activities associated with PTEN inactivation. We searched...